ARTICLE | Clinical News
Supernus' SPN810 meets ADHD endpoints
January 28, 2010 1:09 AM UTC
Supernus Pharmaceuticals Inc. (Rockville, Md.) said oral SPN810 met the secondary efficacy endpoint of significantly reducing conduct problems from baseline as measured by the conduct problem subscale...